Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer, has entered into a definitive agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligators clinical candidate ADC-1013. The collaboration was facilitated by the Johnson & Johnson Innovation Center in London. Currently in phase I clinical trials, ADC-1013 is an agonistic fully human monoclonal antibody targeting CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendritic cells. Stimulation of CD40 on dendritic cells initiates a process leading to a dramatic increase in T effector cells attacking the tumour. In addition, a tumour-specific memory is established leading to long term immunity to the cancer.
Alligator Bioscience will receive an up-front payment plus additional contingent payments upon reaching certain pre-determined development, regulatory and commercial milestones up to a potential total of US$ 700 million. Alligator is also eligible to receive tiered royalties on worldwide net sales upon successful launch and commercialization. In a simultaneous transaction Johnson & Johnson Innovation-JJDC, Inc. will subscribe for new shares of Alligator common stock.
The closing of the transaction is subject to clearance under the Hart-Scott -Rodino Antitrust Improvements Act.
Janssen will be responsible for developing ADC-1013 and will assume responsibility for the clinical studies once the current phase I dose escalation study is complete. Janssen will have exclusive rights to develop and commerci alize ADC-1013 initially targeting a number of solid tumours and haematological cancers and will assume responsibility for all additional research, development, manufacturing, regulatory and commercialization activities.
“This is a key milestone for Alligato r Bioscience said Peter Benson, chairman of the board of directors. ADC-1013, based on a promising and positive pre-clinical data package, is now in phase I clinical trials. We are very pleased to welcome this collaboration with a leading, global oncology company and look forward to working together to ensure ADC-1013 will be benefitting patients as soon as possible.”